Id: acc1347
Group: 2sens
Protein: FOXO3A
Gene Symbol: FOXO3
Protein Id: O43524
Protein Name: FOXO3_HUMAN
PTM: phosphorylation
Site: Thr32
Site Sequence: EPQSRPRSCTWPLQRPELQAS
Disease Category: Cancer
Disease: Breast Cancer
Disease Subtype:
Disease Cellline: MDA-MB-231
Disease Info:
Drug: IBP OV
Drug Info: -
Effect: modulate
Effect Info: "Overexpression of IBP promotes the phosphorylation of mTOR, Akt, and FOXO3a, thereby promoting the growth of breast cancer cells."
Note: Non-conventional drugs
Score: 3.0
Pubmed(PMID): 24113176
Sentence Index:
Sentence:

Sequence & Structure:

MAEAPASPAPLSPLEVELDPEFEPQSRPRSCTWPLQRPELQASPAKPSGETAADSMIPEEEDDEDDEDGGGRAGSAMAIGGGGGSGTLGSGLLLEDSARVLAPGGQDPGSGPATAAGGLSGGTQALLQPQQPLPPPQPGAAGGSGQPRKCSSRRNAWGNLSYADLITRAIESSPDKRLTLSQIYEWMVRCVPYFKDKGDSNSSAGWKNSIRHNLSLHSRFMRVQNEGTGKSSWWIINPDGGKSGKAPRRRAVSMDNSNKYTKSRGRAAKKKAALQTAPESADDSPSQLSKWPGSPTSRSSDELDAWTDFRSRTNSNASTVSGRLSPIMASTELDEVQDDDAPLSPMLYSSSASLSPSVSKPCTVELPRLTDMAGTMNLNDGLTENLMDDLLDNITLPPSQPSPTGGLMQRSSSFPYTTKGSGLGSPTSSFNSTVFGPSSLNSLRQSPMQTIQENKPATFSSMSHYGNQTLQDLLTSDSLSHSDVMMTQSDPLMSQASTAVSAQNSRRNVMLRNDPMMSFAAQPNQGSLVNQNLLHHQHQTQGALGGSRALSNSVSNMGLSESSSLGSAKHQQQSPVSQSMQTLSDSLSGSSLYSTSANLPVMGHEKFPSDLDLDMFNGSLECDMESIIRSELMDADGLDFNFDSLISTQNVVGLNVGNFTGAKQASSQSWVPG

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
FOXO3-Thr32
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
T 32 U Breast cancer Phosphorylation 36797347
T 32 U Non-small cell lung cancer Phosphorylation 35459265

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM
Protein Gene PTM Position Modified sequence Cell Drug pEC50 Regulation Experiment
O43524 FOXO3 P Thr32 SCT(ph)WPLQRPELQASPAK A431 Dasatinib 5.9597 down
O43524 FOXO3 P Thr32 SCT(ph)WPLQRPELQASPAK A431 Gefitinib 5.4679 down
O43524 FOXO3 P Thr32 SCT(ph)WPLQRPELQASPAK A431 Gefitinib 4.9989 down
O43524 FOXO3 P Thr32 SCT(ph)WPLQRPELQASPAKPSGETAADSMIPEEEDDEDDEDGGGR A431 Dasatinib 6.2182 -
O43524 FOXO3 P Thr32;Ser43 SCT(ph)WPLQRPELQAS(ph)PAKPSGETAADSMIPEEEDDEDDEDGGGR A431 Dasatinib 4.3461 -
O43524 FOXO3 P Thr32 SCT(ph)WPLQRPELQASPAKPSGETAADSMIPEEEDDEDDEDGGGR A431 Dasatinib 4.4676 -
O43524 FOXO3 P Thr32 SCT(ph)WPLQRPELQASPAK A431 Dasatinib 7.2352 -
O43524 FOXO3 P Thr32 SCT(ph)WPLQRPELQASPAKPSGETAADSMIPEEEDDEDDEDGGGR A431 Dasatinib 7.1471 -
O43524 FOXO3 P Thr32;Ser43 SCT(ph)WPLQRPELQAS(ph)PAKPSGETAADSMIPEEEDDEDDEDGGGR A431 Dasatinib 8.5156 -
O43524 FOXO3 P Thr32 SCT(ph)WPLQRPELQASPAKPSGETAADSMIPEEEDDEDDEDGGGR A431 Dasatinib 5.8468 -
O43524 FOXO3 P Thr32 SCT(ph)WPLQRPELQASPAKPSGETAADSMIPEEEDDEDDEDGGGR A431 Gefitinib 6.093 -
O43524 FOXO3 P Thr32 SCT(ph)WPLQRPELQASPAK A431 Gefitinib 6.3386 -
O43524 FOXO3 P Thr32 SCT(ph)WPLQRPELQASPAKPSGETAADSMIPEEEDDEDDEDGGGR A431 Gefitinib 5.744 -

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links: